Unlocking Opportunities in the Angiotensin Receptor Blockers (ARBs) Market: Key Growth Trends and Forecast Insights
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What is the Growth Potential of the Angiotensin Receptor Blockers (ARBs) Market, and How Will It Perform by 2034?
In recent times, the market size for angiotensin receptor blockers (ARBs) has experienced consistent growth. The market, which was at $8.51 billion in 2024, is predicted to reach $8.87 billion in 2025, recording a compound annual growth rate (CAGR) of 4.1%. The past period growth can be linked to factors like the widespread incidence of hypertension, clinical effectiveness, the burden of cardiovascular disease, renal protection measures, clinical guidelines, the first-line preference for ARBs, and its cost-effectiveness.
Expectations are high for consistent growth in the angiotensin receptor blockers (ARBs) market over the coming years. The market is projected to reach $10.76 billion by 2029, growing at a compound annual growth rate (CAGR) of 5.0%. This growth throughout the forecast period can be ascribed to several factors such as precision medicine strategies, a focus on combination therapies, market globalization, treatments based on biomarkers, government initiatives and increased hypertension awareness. Key trends forecasted for this period are the adoption of telemedicine, investments in R&D, intensification of generic competition and patent expirations, implementation of digital health solutions for medication adherence, and the emergence of biosimilar competition.
What Combination of Drivers Is Leading to Accelerated Growth in the angiotensin receptor blockers (arbs) Market?
The growth of the angiotensin receptor blockers market is anticipated to be driven by the rising occurrence of cardiovascular diseases. Cardiovascular disease, a health issue affecting the heart or blood vessels, is often coupled with the formation of fatty residues within the arteries or atherosclerosis and a heightened probability of blood clots. Angiotensin receptor blockers help relax veins and arteries, thereby enhancing the heart’s ability to pump blood and lowering blood pressure. This, in turn, can reduce the risk of cardiovascular disease. For instance, the American College of Cardiology, a professional medical organisation based in the US, stated in August 2022 that the predicted rates of cardiovascular risk factors and disease are expected to significantly increase in the US by 2060. As such, the escalating occurrence of cardiovascular diseases is fuelling the growth of the angiotensin receptor blockers market.
Explore Comprehensive Insights Into The Global Angiotensin Receptor Blockers (ARBs) Market With A Free Sample Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8943&type=smp
Who Are the Major Companies Shaping the Competitive Landscape of the Angiotensin Receptor Blockers (ARBs) Market?
Major companies operating in the angiotensin receptor blockers (ARBs) market include:
• Pfizer Inc._x000D_
• Novartis AG_x000D_
• Merck & Co. Inc._x000D_
• AstraZeneca Plc._x000D_
• Bristol-Myers Squibb Company_x000D_
What Are the Key Emerging Trends in the Angiotensin Receptor Blockers (ARBs) Market for the Next Decade?
Leading businesses in the angiotensin receptor blocker market are working on innovations such as angiotensin receptor neprilysin inhibitors to strengthen the range of available treatment options and boost patient outcomes for those with cardiovascular problems. Angiotensin receptor neprilysin inhibitors (ARNIs) are a group of drugs that are intended to manage heart failure. To illustrate, Glenmark Pharmaceuticals, a pharmaceutical company based in India, introduced in January 2023 sacubitril + valsartan tablets. These tablets are designed for heart failure treatment, more specifically for heart failure with reduced ejection fraction (HFrEF). This drug pair is classified under the ARNI (angiotensin receptor neprilysin inhibitors) category. Sacubitril works by enhancing the natriuretic peptide (NP) system to aid in fluid overload reduction and the promotion of blood vessel expansion, whereas valsartan blocks the renin-angiotensin system (RAS) to reduce blood pressure and decrease the strain on the heart. These two working in unison have been shown to help alleviate heart failure symptoms, lower the likelihood of cardiovascular death, and reduce hospitalization rates due to heart failure. The brand name under which they are marketed is Sacu V.
Secure Your Global Angiotensin Receptor Blockers (ARBs) Market Report Now for Fast and Efficient Delivery!
What Major Market Segments Define the Scope and Growth of the Angiotensin Receptor Blockers (ARBs) Market?
The angiotensin receptor blockers (ARBs) market covered in this report is segmented –
1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan
2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications
3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers
Subsegments:
1) By Valsartan: Tablets, Capsules, Injectable Forms
2) By Telmisartan: Tablets, Capsules
3) By Losartan: Tablets, Oral Solution
4) By Irbesartan: Tablets, Oral Solution
5) By Azilsartan: Tablets
6) By Olmesartan: Tablets, Oral Suspension
Which Regions Are Making a Mark in the Angiotensin Receptor Blockers (ARBs) Market Growth?
North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2024. The regions covered in the angiotensin receptor blockers (ARBs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Does the Definition of the Angiotensin Receptor Blockers (ARBs) Market Include?
Angiotensin receptor blockers (ARBs) are medications that dilate (widen) blood vessels and are used to treat conditions such as high blood pressure (hypertension), heart failure, and kidney disease in people with diabetes. Angiotensin is a chemical in the body that causes blood vessels to constrict. This constriction can raise the blood pressure and make the heart work harder.
Browse Through More Similar Reports By The Business Research Company:
Cold Plasma Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/cold-plasma-global-market-report
Porcine Plasma Feed Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/porcine-plasma-feed-global-market-report
Mycoplasma Testing Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/mycoplasma-testing-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
